CureVac AG announced the appointment of Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer. In this role, he will spearhead the company’s research and development activities from discovery to regulatory filing and serve on the company’s Executive team. This appointment represents a key inflection point for CureVac as the company looks to move more assets both CureVac owned and collaboration-based from the lab into the clinic. He has more than 10 years of experience working in academic and clinical research, and over 15 years in the pharmaceutical industry serving in global development leadership positions spanning preclinical-clinical transition, early development to late development, regulatory submissions and product life cycle management. He has worked both in the U.S. as well as in Europe and was last at Eisai Inc., as Senior Vice President & Head, Global Clinical Development for the company’s global Oncology Business Group. He joins the company effective, January 28, 2019 and will be based at the company’s Boston, Massachusetts location, while travelling regularly to the Germany-based sites in Tübingen and Frankfurt.